Claims for Patent: 9,784,743

Summary for Patent: 9,784,743

Title:	Collagens as markers for breast cancer treatment
Abstract:	The specification provides methods of determining whether a subject suffering from ER+/HER2+ breast cancer is likely to respond to adjuvant and neoadjuvant chemotherapy and methods of treating a subject suffering from ER+/HER2+ breast cancer.
Inventor(s):	Brodsky; Alexander S. (Newton, MA), Wang; Yihong (Sharon, MA), Resnick; Murray (Sharon, MA)
Assignee:	Rhode Island Hospital, A Lifespan-Partner (Providence, RI)
Application Number:	15/187,279
Patent Claims:	1. A method of treating a subject diagnosed as having estrogen receptor positive and human epidermal growth factor receptor 2 positive breast cancer, the method comprising: detecting in a sample comprising cancerous breast tissue from the subject an expression level of collagen type 10 alpha 1 that is the same or lower than a collagen type 10alpha 1 reference level, wherein the reference level is the average expression level of collagen type 10 alpha 1 obtained from a population of ER+/HER2+breast tumors; and administering a neoadjuvant or adjuvant chemotherapy to the subject. 2. The method of claim 1, further comprising detecting in the sample an expression level of collagen type 3 alpha 1. 3. The method of claim 1, further comprising detecting in the sample an expression level of collagen type 14 alpha 1. 4. The method of claim 1, further comprising detecting in the sample a total level of tumor infiltrating T lymphocytes (tTILs). 5. The method of claim 1, further comprising detecting in the sample a level of tumor-associated stroma. 6. The method of claim 1, wherein the expression level of collagen type 10 alpha 1 is detected by Northern blot or qPCR analysis of mRNA. 7. The method of claim 1, wherein the expression level of collagen type 10 alpha 1 is detected by immunohistochemistry. 8. The method of claim 2, wherein the expression level of collagen type 3 alpha 1 is detected by Northern blot or qPCR analysis of mRNA. 9. The method of claim 2, wherein the expression level of collagen type 3 alpha 1 is detected by immunohistochemistry. 10. The method of claim 3, wherein the expression level of collagen type 14 alpha 1 is detected by Northern blot or qPCR analysis of mRNA. 11. The method of claim 3, wherein the expression level of collagen type 14 alpha 1 is detected by immunohistochemistry. 12. The method of claim 1, wherein the neoadjuvant chemotherapy comprises administering docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, or a combination thereof. 13. The method of claim 1, wherein the adjuvant chemotherapy comprises administering docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, or a combination thereof. 14. The method of claim 1, wherein the administering further comprises administering a HER2-targeted therapy. 15. The method of claim 14, wherein the HER2-targeted therapy comprises administering trastuzumab, pertuzumab, lapatinib, or a combination thereof. 16. The method of claim 1, wherein the subject is human.

Details for Patent 9,784,743

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2035-06-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2035-06-22
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2035-06-22
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2035-06-22